1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
1,41,00,000 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 242.95 | 225.49 | 176.35 | 145.40 |
| Total Income | 115.78 | 227.37 | 194.33 | 179.48 |
| Profit After Tax | 18.24 | 41.27 | 34.14 | 22.25 |
| EBITDA | 25.46 | 53.88 | 44.09 | 30.69 |
| NET Worth | 197.01 | 178.74 | 137.34 | 103.15 |
| Total Borrowing | 3.85 | 6.79 | 5.11 | 1.50 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹65.51 (+1.93%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹535.60 (-0.34%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,113.00 (+4.28%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,520.20 (-0.78%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹163.00 (-0.61%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.01 (-0.40%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹138.70 (-0.18%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹38.13 (-4.65%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.00 (+0.00%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹273.75 (+0.09%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹255.30 (+2.51%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹112.00 (+1.82%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹254.50 (+1.13%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding the working capital requirements. | 72.50 |
| 2 | General corporate purposes. |
About Hindustan Laboratories IPO
Incorporated in 2017, Hindustan Laboratories Limited is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework. The company's roducts are supplied mainly through procurement contracts for central government healthcare projects under the Ministry of Health and Family Welfare via Government of India agencies, as well as through state government agencies and bodies. Hindustan Laboratories Limited supplied products across India to 27 states and Union Territories during the six months ended September 30, 2025, and to 27 states and Union Territories during Fiscal 2025. The company served 343 customers during the six months ended September 30, 2025, and 445, 474, and 439 customers in Fiscal 2025, Fiscal 2024, and Fiscal 2023, respectively. The product portfolio covers a wide range of therapeutic segments addressing both acute and chronic healthcare requirements. These include anti-allergic, anti-diabetic, anti-infective, anti-malarial, antiparasitic, blood-related, cardiac, gastrointestinal, keratolytic, pain and analgesic, respiratory therapies, nutrition
Contact Details
Hindustan Laboratories Ltd. Address302, A Wing,Victory Park, Chandavarkar Road,Borivali West,Mumbai, Maharashtra, 400092022-42460500compliance@hindlab.comVisit Website